which is why it's considered a Dividend King despite its seemingly short history. By spinning off, AbbVie has been able to ...

With a market cap of $356.2 billion, North Chicago, Illinois-based AbbVie Inc. (ABBV) operates in the pharmaceutical sector.

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this ...

AbbVie has a lower P/E than the aggregate P/E of 112.06 of the Biotechnology industry. Ideally, one might believe that the ...

Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 39%. Looking ahead, revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared ...

Corporate insiders own 0.25% of the company’s stock. Several research analysts recently issued reports on ABBV shares. Wells Fargo & Company increased their target price on shares of AbbVie from ...

Bernstein has recently initiated AbbVie Inc (ABBV) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on June 5, 2024, HSBC Securities had raised the stock ...

Share count may tend to fluctuate in big pharma names as acquisitions come into the pipeline, which may be purchased with shares if advantageous due to share price appreciation. Long-term debt has ...

The brokerage currently has an outperform rating on the stock. Several other equities analysts have also recently issued reports on the company. Barclays boosted their target price on AbbVie from ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.